Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04851717 · ClinicalTrials.gov registry record · Phase 2

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

A Phase 2 study of Pediatric ALL, sponsored by Acacia Pharma.

Active
Registry status
Phase 2
Development phase
100
Enrollment target
8
Study locations

NCT04851717 is a Phase 2 study of Pediatric ALL that is active but no longer recruiting, run by Acacia Pharma. The registered enrollment target is 100 participants, below the 1,643-participant average among 21 other Pediatric ALL trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04851717, a Phase 2 study of Pediatric ALL, is active but no longer recruiting, sponsored by Acacia Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
8
Study locations

Study Summary

To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures

Conditions Studied

Interventions

  • DRUG Remimazolam

Study Locations (8)

California

  • Stanford University - Palo Alto
  • University of California Davis Children's Hospital - Sacramento

Other

  • Rigshospitalet - Copenhagen
  • Odense Universitetshospital - Odense

Massachusetts

  • Boston Children's Hospital - Boston

Minnesota

  • University of Minnesota Masonic Children's Hospital - Minneapolis

Pennsylvania

  • University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh - Pittsburgh

Texas

  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-11-15
Est. Completion 2027-10
Phase Phase 2

Sponsor

Acacia Pharma

9 total trials

What the Registry Record Tells You About NCT04851717

The ClinicalTrials.gov registry entry for NCT04851717 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,643-participant average among 21 other Pediatric ALL trials with a reported enrollment target (94% lower). The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pediatric ALL appearing as the primary indexed condition, and to 1 intervention - of which Remimazolam is the first listed.

NCT04851717 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Other, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04851717 about?

NCT04851717 is a clinical study titled "Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures". To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures

What is the current status of trial NCT04851717?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2021-11-15. Estimated completion is 2027-10.

What conditions does trial NCT04851717 study?

This clinical trial studies the following conditions: Pediatric ALL.

What interventions are being tested in trial NCT04851717?

The interventions under investigation include: Remimazolam (DRUG).

Who is sponsoring clinical trial NCT04851717?

This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04851717 being conducted?

This trial has 8 study locations across California, Massachusetts, Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pediatric ALL

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.